Last reviewed · How we verify
PYRILAMINE
PYRILAMINE is a marketed drug primarily indicated for menstrual cramps, with a key composition patent expiring in 2028. Its primary strength lies in its established market presence and long-term patent protection. The primary risk is the potential increase in competition following the patent expiry in 2028.
At a glance
| Generic name | PYRILAMINE |
|---|---|
| Drug class | Central Nervous System Stimulant [EPC] |
| Modality | Small molecule |
| Phase | FDA-approved |
| First approval | 1973 |
Approved indications
- Menstrual Cramps
- Bloating
- Water Weight Gain
- Headache
- Backache
- Muscle Aches
- Fatigue
Common side effects
Key clinical trials
- Pharmacological Modulation of Peripheral Nerve Excitability (NA)
- Efficacy and Safety of Pediatric Drugs in Nasal Congestion (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |